MARSHALL & POPP, LLC

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Biopharmaceutical industry trade association.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $40,000.00 income · posted Apr 21, 2025

Bills named in this filing 6

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 2882
Central Coast of California Conservation Act of 2025
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
SCONRES 7
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…

Lobbying activity 4

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act.

Trade (domestic/foreign)

Issues related to tariff and trade policy.

Pharmacy

Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 2882, FY2024 Further Consolidated Appropriations Act. Issues related to the 340B program.

Budget/Appropriations

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.